U.S.-based pharmaceutical company CURE Pharmaceutical has announced a partnership with PMI, a subsidiary of Factoria Bogar in Guadalajara, Mexico to extends its work in Mexico.
PMI will have it’s access to CURE’s innovative drug delivery platform, CUREform for its drug formulation. Also, PMI becomes CURE’s distribution partner in Mexico for CURE’s wellness products, such as its vitamin D supplement, sleep, and CBD combination products.
“This collaboration enables us to reach new markets with our suite of wellness products as well as prompt innovation with new drug formulations and conduct valuable patient studies on drug efficacy. This is a valuable partnership from both a revenue perspective as well as an opportunity to expand product offerings and research collaborations,” stated Rob Davidson, CEO of CURE.
The CURE collaboration with PMI will introduce several development initiatives with its proprietary prebiotic product from Agave in combination with CBD that leverages the CUREform novel delivery platform for the treatment of multiple GI indications.
With CUREform, the delivery of cannabinoids is more accessible and more effective because it offers enhanced bioavailability, simple precision of dosing, and greater palatability. There are patient studies planned for Mexico to improve drug efficacy with CBD and prebiotics.
